HCW Biologics Inc. (HCWB )

Currency in USD Disclaimer
$0.45 -$0.09 (-17.28%)
Open 02/05/2025
$0.42
$0.49
$0.21
$2.52

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol HCWB
  • Company HCW Biologics Inc.
  • Price $0.45
  • Changes Percentage -17.28
  • Change -0.094
  • Day Low $0.42
  • Day High $0.49
  • Year High $2.52
  • Year Low $0.21
  • Market Cap $16,494,785
  • Price Avg 50 EMA (D) $0.44
  • Price Avg 200 EMA (D) $0.67
  • Exchange NASDAQ
  • Volume 1,997,784
  • Average Volume 15,930,925
  • Open $0.46
  • Previous Close $0.54
  • EPS -1.01
  • PE -0.43
  • Earnings Announcement 2025-04-01 12:00:00
  • Shares Outstanding $37,823,400

Company brief: HCW BIOLOGICS INC. (HCWB )

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

HCWB Corporation News

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

February 3, 2025 at 12:15 pm ET

globenewswire.com -- MIRAMAR, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and d...

Income Statement